HUTCHMED Announces Positive Results for Lung Cancer Drug Combination

HUTCHMED announces that its drug combination, ORPATHYS® Plus TAGRISSO®, has shown statistically significant and clinically meaningful improvements in progression-free and overall survival for patients with MET-driven EGFR-mutated lung cancer.

17 Aug, 00:00 — 17 Aug, 00:00

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual8d ago

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® - Taiwan News

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® Taiwan News

Read full article →

PERSPECTA

PERSPECTA

HUTCHMED Announces Positive Results for Lung Cancer Drug Combination

Sources

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® - Taiwan News

Related Stories

Sandra Bullock Discusses Children's Reaction to Partner's ALS Battle

West Nile Virus Cases Rise in Balkan Region

Extreme Heat Causes 35,000 Excess Deaths in Europe

Unprecedented Salmonella outbreak in Belgium with at least 306 cases

PERSPECTA